Wearable injectors promise to take out the pain out of injections

Enable Injections, the developer and manufacturer of a new wearable injector technology platform that enables easy, comfortable patient self-administration of large volume drugs subcutaneously, announced today that it has completed its first-in-human pilot trial. The study evaluated dose delivery, injection pain and ease of use in subcutaneous self-delivery.

Ten healthy subjects served as their own controls. Each self-administered four doses of saline subcutaneously with the Enable Injector, an advanced drug delivery device. The Enable Injector was used to successfully deliver both low (1.5 mL) and high (2 x 10 mL) doses.

“An easy to use, relatively painless injector like this may open the door not only for new pharmaceuticals that may not be possible without this type of device, but also significantly improve patient compliance,” said principal investigator Gary Ansel, MD, Associate Medical Director of the OhioHealth Research and Innovation Institute in Columbus. “We can foresee the potential for improved patient outcomes, cost savings and reduced hospital stays.”

Wearable injectors are designed to address the challenges of complexity, patient compliance and the high costs of delivering large volume drugs such as biologics. The Enable Injector was developed and designed based on input from dozens of human factors studies to make self-injection safe, easy, comfortable and convenient for patients – yet cost-effective for the pharmaceutical industry and payers.

“We are extremely pleased with the results of the pilot trial and the performance of the Enable Injector,” said Michael D. Hooven, President and CEO of Enable Injections. “We look forward to additional clinical trials to meet the pressing need for new, patient-pleasing injection technology that can unlock the promise of biologics and that can also reduce drug formulation and health system costs.”

Enable Injections is currently involved in multiple feasibility and collaboration programs with several pharmaceutical and biotechnology companies.